COVID-19: NAFDAC says Chloroquine trial continues in Nigeria despite suspension from WHO


Director-General of NAFDAC, Prof. Mojisola Adeyeye has noted that Nigeria will continue with the solidarity trial of chloroquine for COVID-19 treatment.



Adeyeye said on a television programme on Tuesday:  “There is data to prove that hydroxychloroquine worked for many COVID-19 patients. Therefore, we would continue our own clinical trials in Nigeria.”
This is contrary to the suspension of trial announced on Monday by the World Health Organisation (WHO) as a result of “safety concerns”.
According to the international agency, a report published by Lancet, which indicated that more people are dying from the use of the drug, influenced its decision.
NAFDAC DG added, “Hydroxychloroquine has been proved to work at a mild stage. So the potency depends on the severity of the disease in the patient’s body.
“If medical doctors, research scientists, pharmacists, herbal experts work together, we should conclude the clinical trial in three to four months. The narrative might change afterwards but for now, we believe in hydroxychloroquine.”

Comments

Popular posts from this blog

Fear women: Nigerians react as woman cut off husband’s penis

Niche hunting shouldn’t be top priority for writers, says Dokubo as she unravels basic tips for beginners

The Mindset every Writer must have